GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Cardiol Therapeutics CRDL.TO · CAD

Health Care · Toronto Stock Exchange · 🇨🇦 Canada

Compare

1.48

+4.96%

Close of 9 Nov 2026, in CAD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CAD, from our data supplier.

FY2025

Revenue

—

FY2017FY2025

Net income

−C$33.8m

FY2017FY2025

Free cash flow

−C$23.9m

FY2017FY2025

Shareholders' equity

C$17.9m

FY2017FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue————C$78,760C$78,760———
Research and developmentC$14.0mC$14.0mC$14.2mC$19.0mC$10.9mC$10.5mC$3.5mC$1.5mC$441,257
Operating income−C$34.3m−C$40.3m−C$29.8m−C$50.3m−C$45.5m−C$20.6m−C$13.6m−C$7.5m−C$1.6m
Net income−C$33.8m−C$36.7m−C$28.1m−C$11.5m−C$24.7m−C$20.6m−C$14.0m−C$15.9m−C$1.7m
Diluted earnings per share-0.34-0.45-0.43-0.18-0.57-0.63-0.43-0.48-0.07

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assetsC$23.6mC$31.9mC$36.7mC$62.0mC$87.9mC$15.9mC$15.5mC$24.7mC$3.2m
Cash and short-term investmentsC$21.4mC$30.6mC$34.9mC$59.5mC$83.9mC$14.0mC$7.0mC$16.7mC$2.4m
Total liabilitiesC$5.7mC$7.1mC$8.5mC$9.8mC$11.6mC$2.6mC$830,828C$2.4mC$366,757
DebtC$125,523C$158,532C$158,532C$72,871C$117,579C$156,566C$190,753C$269,220C$190,043
Shareholders' equityC$17.9mC$24.7mC$28.2mC$52.2mC$76.2mC$13.3mC$14.7mC$22.3mC$2.9m
Shares outstanding100m82m65m64m43m33m33m33m23m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations−C$23.9m−C$25.1m−C$25.2m−C$27.2m−C$23.6m−C$9.2m−C$11.4m−C$10.9m−C$1.3m
Capital spending−C$24,484−C$21,290−C$64−C$74,709−C$12,916−C$40,602−C$424,305−C$13,791−C$29,171
Free cash flow−C$23.9m−C$25.1m−C$25.2m−C$27.3m−C$23.6m−C$9.2m−C$11.8m−C$10.9m−C$1.3m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Operating income−C$7.9m−C$9.7m−C$8.0m−C$10.2m−C$7.7m−C$8.4m−C$10.0m−C$14.1m
Net income−C$6.1m−C$10.8m−C$7.2m−C$10.0m−C$8.4m−C$8.3m−C$8.2m−C$12.7m
Diluted earnings per share-0.05-0.09-0.07-0.10-0.08-0.08-0.10-0.16
Cash from operations−C$4.0m−C$7.0m−C$5.0m−C$6.0m−C$4.0m−C$7.0m−C$5.0m−C$7.0m
Total assetsC$29.4mC$31.4mC$23.6mC$12.9mC$19.9mC$25.5mC$31.9mC$17.5m
Cash and short-term investmentsC$26.1mC$27.7mC$21.4mC$11.6mC$18.2mC$23.3mC$30.6mC$15.9m
DebtC$41,308C$39,792C$125,527C$134,195C$142,556C$150,662C$158,529C$165,985
Shareholders' equityC$24.0mC$24.2mC$17.9mC$9.6mC$11.8mC$17.6mC$24.7mC$10.4m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-12.0%10.7%—
Net income43.2%10.4%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Price to earnings-3.9-4.1-2.6-3.8-4.1-4.4-10.7-9.2

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.